Scientists Are Using Microparticles To Develop a Self-Boosting Vaccine

  • 2 years ago
Scientists Are Using Microparticles, to Develop a, Self-Boosting Vaccine.
'Newsweek' reports that scientists are developing
a one-jab, self-boosting vaccine that can
deliver multiple doses at different times.
According to new research, one shot
could provide multiple rounds of
inoculation thanks to microparticles.
Scientists claim the microparticles
could be used to combat a number of
illnesses, including measles and COVID.
The team at MIT's Koch Institute for Integrative Cancer Research
in Cambridge, Massachusetts, says the technology could be
particularly useful for administering childhood vaccinations.
This is a platform that can be broadly
applicable to all types of vaccines,
including recombinant protein-based
vaccines, DNA-based vaccines,
even RNA-based vaccines, Dr. Ana Jaklenec,
senior author of the study,
via 'Newsweek'.
Understanding the process
of how the vaccines are released,
which is what we described in this paper,
has allowed us to work on formulations
that address some of the instability
that could be induced over time, Dr. Ana Jaklenec,
senior author of the study,
via 'Newsweek'.
'Newsweek' reports that the particles are made from PLGA, a biocompatible polymer already approved for use in medical and prosthetic devices. .
We believe these core shell particles
have the potential to create a safe,
single-injection, self-boosting vaccine
in which a cocktail of particles with
different release times can be created
by changing the composition, Professor Robert Langer,
co-senior author of the study,
via 'Newsweek'.
Such a single injection approach has the
potential to not only improve patient
compliance but also increase cellular and
humoral immune responses to the vaccine, Professor Robert Langer,
co-senior author of the study,
via 'Newsweek'.
Such a single injection approach has the
potential to not only improve patient
compliance but also increase cellular and
humoral immune responses to the vaccine, Professor Robert Langer,
co-senior author of the study,
via 'Newsweek'

Recommended